Pharnext

We strive to address serious unmet medical needs. We believe that diseases require solutions that master their complexity by combining therapeutics in a synergistic and/or additive way. We aim to become the recognized world leader in this approach.

We are dedicated to treating serious chronic diseases by developing novel, first-in-class treatments. We leverage our artificial intelligence (AI)-based PLEOTHERAPY™ platform technology to discover, develop and deliver breakthrough therapies to patients. These therapies consist of repurposed or New Chemical Entity (NCE) drug combinations with potentially high benefit/risk ratio and an accelerated/cost-efficient development pathway.

PLEOTHERAPY™, our proprietary technology platform, is based on network pharmacology. This new and innovative R&D paradigm leverages genomic big data and artificial intelligence tools to systematically develop disease molecular networks: a set of interconnected potential disease targets. These networks are then used to deduce, in silico and experimentally, combinations of generic compounds approved for unrelated indications and/or NCEs to hit multiple highly relevant disease targets. These new therapies, called PLEODRUG™, are formulated at optimal doses offering several potential key advantages including improved efficacy and safety.

PLEODRUG™ candidates are currently in clinical development for the treatment of Charcot-Marie-Tooth disease type 1A and Alzheimer’s disease. We believe that this is just the beginning and that our proprietary technology is poised to provide therapies for any disease.